PINC Quote, Financials, Valuation and Earnings

Cryo-Cell International has a net margin of 10.36% compared to Premier's net margin of 3.55%. Premier's return on equity of 3.44% beat Cryo-Cell International's return on equity of --.

Premier has a consensus price target of $22.00, signalling downside risk potential of -4.27%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 66.02%. Given that Cryo-Cell International has higher upside potential than Premier, analysts believe Cryo-Cell International is more attractive than Premier.

Premier has a beta of 0.541, which suggesting that the stock is 45.858% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.595%.

Premier has a quarterly dividend of $0.21 per share corresponding to a yield of 3.66%. Cryo-Cell International offers a yield of 12.7% to investors and pays a quarterly dividend of $0.15 per share. Premier pays 79.64% of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend. Premier's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Cryo-Cell International's is not.

Premier quarterly revenues are $261.4M, which are larger than Cryo-Cell International quarterly revenues of $8M. Premier's net income of $27.1M is higher than Cryo-Cell International's net income of $282.9K. Notably, Premier's price-to-earnings ratio is 42.56x while Cryo-Cell International's PE ratio is 512.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Premier is 1.77x versus 1.31x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Evolent Health has a net margin of 10.36% compared to Premier's net margin of -13.36%. Premier's return on equity of 3.44% beat Evolent Health's return on equity of -10.73%.

Premier has a consensus price target of $22.00, signalling downside risk potential of -4.27%. On the other hand Evolent Health has an analysts' consensus of $15.31 which suggests that it could grow by 105.47%. Given that Evolent Health has higher upside potential than Premier, analysts believe Evolent Health is more attractive than Premier.

Premier has a beta of 0.541, which suggesting that the stock is 45.858% less volatile than S&P 500. In comparison Evolent Health has a beta of 1.042, suggesting its more volatile than the S&P 500 by 4.162%.

Premier has a quarterly dividend of $0.21 per share corresponding to a yield of 3.66%. Evolent Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Premier pays 79.64% of its earnings as a dividend. Evolent Health pays out -32.59% of its earnings as a dividend. Premier's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Premier quarterly revenues are $261.4M, which are smaller than Evolent Health quarterly revenues of $483.6M. Premier's net income of $27.1M is higher than Evolent Health's net income of -$64.6M. Notably, Premier's price-to-earnings ratio is 42.56x while Evolent Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Premier is 1.77x versus 0.36x for Evolent Health. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of 10.36% compared to Premier's net margin of -2.6%. Premier's return on equity of 3.44% beat Omnicell's return on equity of 1.73%.

Premier has a consensus price target of $22.00, signalling downside risk potential of -4.27%. On the other hand Omnicell has an analysts' consensus of $39.83 which suggests that it could grow by 31.16%. Given that Omnicell has higher upside potential than Premier, analysts believe Omnicell is more attractive than Premier.

Premier has a beta of 0.541, which suggesting that the stock is 45.858% less volatile than S&P 500. In comparison Omnicell has a beta of 0.776, suggesting its less volatile than the S&P 500 by 22.397%.

Premier has a quarterly dividend of $0.21 per share corresponding to a yield of 3.66%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Premier pays 79.64% of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend. Premier's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Premier quarterly revenues are $261.4M, which are smaller than Omnicell quarterly revenues of $269.7M. Premier's net income of $27.1M is higher than Omnicell's net income of -$7M. Notably, Premier's price-to-earnings ratio is 42.56x while Omnicell's PE ratio is 66.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Premier is 1.77x versus 1.25x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

Phreesia has a net margin of 10.36% compared to Premier's net margin of -3.38%. Premier's return on equity of 3.44% beat Phreesia's return on equity of -16.36%.

Premier has a consensus price target of $22.00, signalling downside risk potential of -4.27%. On the other hand Phreesia has an analysts' consensus of $31.43 which suggests that it could grow by 28.33%. Given that Phreesia has higher upside potential than Premier, analysts believe Phreesia is more attractive than Premier.

Premier has a beta of 0.541, which suggesting that the stock is 45.858% less volatile than S&P 500. In comparison Phreesia has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.243%.

Premier has a quarterly dividend of $0.21 per share corresponding to a yield of 3.66%. Phreesia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Premier pays 79.64% of its earnings as a dividend. Phreesia pays out -- of its earnings as a dividend. Premier's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Premier quarterly revenues are $261.4M, which are larger than Phreesia quarterly revenues of $115.9M. Premier's net income of $27.1M is higher than Phreesia's net income of -$3.9M. Notably, Premier's price-to-earnings ratio is 42.56x while Phreesia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Premier is 1.77x versus 3.28x for Phreesia. Usually stocks with elevated PS ratios are considered overvalued.